(Q36790158)

16 August 2017

1 reference

title

Pancreatic cancer: an update (English)

1 reference

16 August 2017

1 reference

Hedy Lee Kindler

1

1 reference

16 August 2017

1 May 2007

1 reference

16 August 2017

Current Oncology Reports

1 reference

16 August 2017

9

1 reference

16 August 2017

170-176

1 reference

16 August 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1007/s11912-007-0018-z

16 August 2017

0 references

cites work

Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes

1 reference

12 December 2020

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate

1 reference

12 December 2020

Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial

1 reference

12 December 2020

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

1 reference

12 December 2020

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

1 reference

12 December 2020

Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis

1 reference

12 December 2020

A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer

1 reference

12 December 2020

Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma

1 reference

12 December 2020

Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer

1 reference

12 December 2020

High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma

1 reference

12 December 2020

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer

1 reference

12 December 2020

Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial

1 reference

12 December 2020

Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases

1 reference

12 December 2020

Cancer statistics, 2006

1 reference

12 December 2020

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial

1 reference

12 December 2020

Chemotherapy for advanced pancreatic cancer: past, present, and future

1 reference

12 December 2020

Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy

1 reference

12 December 2020

Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer

1 reference

12 December 2020

Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice

1 reference

12 December 2020

Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program

1 reference

12 December 2020

Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

12 December 2020

In focus: advanced pancreatic cancer.

1 reference

12 December 2020

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

1 reference

12 December 2020

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

12 December 2020

EGF receptor antagonism improves survival in a murine model of pancreatic adenocarcinoma

1 reference

12 December 2020

Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas

1 reference

12 December 2020

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

12 December 2020

10.1007/S11912-007-0018-Z

Identifiers

DOI

1 reference

16 August 2017

1 reference

PubMed ID

17430687